Search

Author/Creator Houisse, Ivan

1. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. (1st November 2016)

Authors:
Jakubowiak, Andrzej J.; Campioni, Marco; Benedict, Ágnes; Houisse, Ivan; Tichy, Eszter; Giannopoulou, Andromachi; Aggarwal, Sanjay K.; Barber, Beth L.; Panjabi, Sumeet
Journal:
Journal of medical economics
Issue:
Volume 19:Number 11(2016)
Page Start:
1061
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Issue 12 (2nd December 2017)

Authors:
Jakubowiak, Andrzej J.; Houisse, Ivan; Májer, István; Benedict, Ágnes; Campioni, Marco; Panjabi, Sumeet; Ailawadhi, Sikander
Journal:
Expert review of hematology
Issue:
Volume 10:Issue 12(2017)
Page Start:
1107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. (1st January 2021)

Authors:
Nilsson, Fredrik O. L.; Gal, Peter; Houisse, Ivan; Ivanova, Jasmina I.; Asanin, Sandra T.
Journal:
Journal of medical economics
Issue:
Volume 24:Number 1(2021)
Page Start:
447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗